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The fusion gene CBFB-MYH11 is generated by the chromosome 16 inversion associated with acute myeloid
leukemias. This gene encodes a chimeric protein involving the core binding factor b (CBFb) and the smooth-
muscle myosin heavy chain (SMMHC). Mouse model studies suggest that this chimeric protein CBFb-SMMHC
dominantly suppresses the function of CBF, a heterodimeric transcription factor composed of DNA binding
subunits (CBFa1 to 3) and a non-DNA binding subunit (CBFb). This dominant suppression results in the block-
age of hematopoiesis in mice and presumably contributes to leukemogenesis. We used transient-transfection
assays, in combination with immunofluorescence and green fluorescent protein-tagged proteins, to monitor sub-
cellular localization of CBFb-SMMHC, CBFb, and CBFa2 (also known as AML1 or PEBP2aB). When ex-
pressed individually, CBFa2 was located in the nuclei of transfected cells, whereas CBFb was distributed
throughout the cell. On the other hand, CBFb-SMMHC formed filament-like structures that colocalized with
actin filaments. Upon cotransfection, CBFa2 was able to drive localization of CBFb into the nucleus in a dose-
dependent manner. In contrast, CBFa2 colocalized with CBFb-SMMHC along the filaments instead of local-
izing to the nucleus. Deletion of the CBFa-interacting domain within CBFb-SMMHC abolished this CBFa2
sequestration, whereas truncation of the C-terminal-end SMMHC domain led to nuclear localization of CBFb-
SMMHC when coexpressed with CBFa2. CBFa2 sequestration by CBFb-SMMHC was further confirmed in
vivo in a knock-in mouse model. These observations suggest that CBFb-SMMHC plays a dominant negative
role by sequestering CBFa2 into cytoskeletal filaments and aggregates, thereby disrupting CBFa2-mediated
regulation of gene expression.
The pericentric inversion of chromosome 16 [inv(16)(p13q22)]
is a cytogenetic abnormality consistently associated with acute
myeloid leukemia (AML) subtype M4Eo (2, 21), a variant of
subtype M4 with abnormal eosinophils in the bone marrow and
sometimes in the peripheral blood. The inversion results in the
reciprocal fusions of two genes: the MYH11 gene (16p13), which
encodes the smooth-muscle myosin heavy chain (SMMHC),
and the CBFB gene (16q22), which encodes the b subunit of
the core binding factor (CBFb) (24). The chimeric gene CBFB-
MYH11 fuses most of the 59 coding region of CBFB in frame
with the 39 portion of MYH11, resulting in the production of
the chimeric protein CBFb-SMMHC. The reciprocal fusion,
MYH11-CBFB, is not believed to be important since its expres-
sion is below detectable levels in leukemic cells and it is de-
leted in some patients with an unbalanced inversion (24, 25,
29).
CBFb is the heterodimeric partner of CBFa proteins, and
together they constitute the core binding factors (CBF). CBF
was initially identified as a transcriptional regulator of Molo-
ney murine leukemia virus (50, 51) and polyomavirus (4, 18, 36,
37, 43) in mice, and it was subsequently shown to be an im-
portant transcriptional activator of genes involved in mamma-
lian hematopoiesis and bone development (5, 12, 14, 15, 20, 32,
40, 46). Monomeric CBFa proteins bind DNA, albeit weakly
(3, 50). Although CBFb does not make any detectable direct
contact with DNA (50), it enhances the DNA binding affinity
of the CBFa proteins (4, 36). While CBFb is expressed from a
single gene in the human and mouse, there are three CBFa
genes, all of which encode the so-called runt domain (3, 22,
54), which is required for both DNA binding and interaction
with CBFb. One of the three genes, CBFA2, also known as
AML1 or PEBP2aB, is located on human chromosome 21 and
is involved in several different leukemias as a result of trans-
locations (16, 31, 34, 35, 41). Chromosomal inversions and
translocations involving either CBFB or CBFA2 are the most
frequent cytogenetic abnormalities in human AMLs (27).
Gene-targeting experiments in mice have demonstrated that
the CBFa2 and CBFb subunits are likely to function together
as a complex in vivo. Homozygous disruption of either Cbfa2
(39, 48) or Cbfb (42, 49) in mice produces an identical pheno-
type: both Cbfa22/2 and Cbfb2/2 embryos demonstrate a fail-
ure of definitive hematopoiesis in the liver, and in both cases
the embryos die at around day 12.5 due to extensive hemor-
rhages.
The inv(16) chimeric gene CBFB-MYH11 has been shown
to exert a dominant negative effect in vivo by a mouse knock-
in experiment (8). CBFB-MYH11 was introduced into the
mouse genome to replace one copy of the Cbfb gene. The ex-
pression of this chimeric gene was controlled by the endog-
enous Cbfb promoter, thus simulating the condition in leu-
kemic patients. CBFb-SMMHC was found to dominantly
suppress the function of the CBFa2:CBFb heterodimer, since
mouse embryos heterozygous for the knock-in Cbfb-MYH11
gene (CbfbCBFB-MYH11/1) displayed a phenotype similar to that
of Cbfb2/2 and Cbfa22/2 embryos, i.e., failure of definitive he-
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matopoiesis and midgestation lethality. In vitro, the chimeric
protein was shown to retain its ability to interact with CBFa pro-
teins and participate in the formation of protein-DNA com-
plexes (23). Although presence of the chimeric protein reduces
CBF DNA-binding activity in cultured Ba/F3 lymphoid and
32D c13 myeloid cells (6), it is not clear how this reduction was
achieved. Unlike wild-type CBFb, CBFb-SMMHC can poten-
tially form dimers and multimers via the rod-like domain of the
myosin chain (23, 25).
Two possible mechanisms could explain the dominant nega-
tive effect of the chimeric CBFb-SMMHC protein. One is that
CBFb-SMMHC, via heterodimerization with CBFa2, can as-
semble into a ternary complex at the core sites within promot-
ers of target genes and interfere with the regulation of gene
expression. The second possibility is that CBFb-SMMHC, with
its capacity to form multimers, can sequester CBFa2 into
nonfunctional complexes, thus preventing it from regulating
transcription of target genes. Previous studies by our group
demonstrated that CBFb-SMMHC can form rod-like nuclear
structures as well as cytoplasmic stress fibers in NIH 3T3 cells
stably transfected with a CBFB-MYH11 cDNA construct (53).
However, the effect on CBFa2 subcellular localization by
CBFb-SMMHC has not been fully examined. In this study, we
used transient-transfection assays in combination with immuno-
fluorescence and green fluorescent protein (GFP) tags to dem-
onstrate that CBFb-SMMHC does, in fact, sequester CBFa2
in abnormal locations. We also demonstrated that the seques-
tration requires the abilities of CBFb-SMMHC to interact with
CBFa2 and to multimerize. This observed sequestration can
at least partially explain the dominant negative effect of the
CBFb-SMMHC protein on CBF function in leukemogenesis.
MATERIALS AND METHODS
Construction of plasmids. pEGFP-C2, the vector expressing a modified GFP
(EGFP) under the control of the cytomegalovirus (CMV) promoter, was ob-
tained from Clontech. This vector allows for in-frame fusion of target genes at
the COOH-terminal end of EGFP. Plasmids pCBFB, pCBFB-MYH11, and pCbfa2,
each containing the entire coding region of the respective genes under the con-
trol of CMV promoter, have been described previously (23, 26, 45). pCBFB car-
ries the CBFb187 isoform, pCBFB-MYH11 carries the CBFb-SMMHC204 iso-
form (26), and pCbfa2 carries the mouse CBFa2451 isoform. EGFP fusion
constructs pEGFP-CBFB, pEGFP-CBFB-MYH11, and pEGFP-Cbfa2 were gen-
erated following standard subcloning procedures by using these reported full-
length cDNA plasmids.
The deletion construct pCBFB-MYH11DN2-11 was generated by PCR-directed
mutagenesis. A 436-bp fragment with a 30-bp deletion immediately 39 to the
initiating ATG was amplified with forward primer 59-ATATGAATTCGGGAA
GATGTTCGAGAACGAGGAG-39 and reverse primer 59-CAGTAAGCTTAC
CTCCATTTCCTCCCG-39 and with pCBFB-MYH11 as the template. This PCR
fragment was digested with EcoRI (the recognition site is within the primer) and
StuI (the recognition site is within the CBFB-encoding region) and used to re-
place the EcoRI-StuI fragment of pCBFB-MYH11 to make CBFB-MYH11DN2-11,
which was subcloned into pBluescript-KS (Stratagene) and pEGFP-C2 by stan-
dard methods.
pCBFB-MYH11DC390 was generated by digesting pCBFB-MYH11 with SmaI
and EcoRI to release the small fragment containing a partial cDNA and ligat-
ing with the pCMV vector. pCBFB-MYH11DC303 was generated by digesting
pCBFB-MYH11 with BglII, filling in the ends with the Klenow subunit of DNA
polymerase, and then digesting with EcoRI to release the partial cDNA, which
was then ligated to the pCMV vector. pCBFB-MYH11DC95 was generated by
digesting pCBFB-MYH11 with BsrDI, filling in the ends with the Klenow subunit
of DNA polymerase, and digesting with EcoRI to release the partial cDNA,
which was then ligated to the pCMV vector.
pEGFP-CBFB-MYH11 was digested with SmaI and BamHI to release the 39
end of CBFB-MYH11, and then the large fragment was religated to generate
pEGFP-CBFB-MYH11DC390. pEGFP-CBFB-MYH11DC303 was constructed by
removing the BglII-BamHI fragment of pEGFP-CBFB-MYH11. pEGFP-CBFB-
MYH11DC95 was generated by digesting pCBFB-MYH11 with BsrDI, filling in
the ends with the Klenow subunit of DNA polymerase, digesting again with
EcoRI, and ligating the insert into pEGFP-C2 digested with EcoRI and SmaI.
All the constructs generated were confirmed by restriction digests, and all
those involving fusions at their 59 ends were also confirmed by sequencing across
the fusion junctions. In vitro transcription-translation experiments and Western
analysis of transiently transfected cells (see below) confirmed the production of
proteins of expected sizes.
Antibodies. a3043, a rabbit polyclonal antibody specific for CBFa2, and b141.2,
a mouse monoclonal antibody against CBFb, have been described previously (5,
49). Texas-red-labeled phalloidin was obtained from Molecular Probes for actin
labeling. Fluorescein-labeled affinity purified secondary antibodies against mouse
immunoglobulin G (IgG) and rabbit IgG were obtained from Kirkegaard &
Perry Laboratories Inc. Texas-red-labeled affinity purified secondary antibodies
against mouse IgG and rabbit IgG were obtained from Vector Laboratories. The
primary antibodies were diluted in Triton buffer (phosphate-buffered saline [PBS],
0.3% Triton X-100, 2% bovine serum albumin [BSA]) at working dilutions of
1:10, and the secondary antibodies were diluted in the same buffer at the rec-
ommended dilutions.
Cell culture and DNA transfection. NIH 3T3 cells were maintained in Dulbec-
co’s modified Eagle medium supplemented with 10% (vol/vol) heat-inactivated
newborn calf serum. DNA transfections were performed with lipofectamine
(GIBCO-BRL) according to the manufacturer’s instructions. Fifty thousand cells
were plated onto a 15-mm-diameter circular glass coverslip in a 12-well tissue
culture dish for 12 h at 37°C before transfection. A maximum of 2.5 mg of DNA
was used for each transfection. Twenty percent serum was added to cells at 5 h
posttransfection, and the cells were cultured for 12 h at 37°C. The culture me-
dium was replaced with complete medium at this time, and cells were collected
for fixation or immunoprecipitation at times ranging from 12 to 48 h after addi-
tion of fresh media.
Cell fractionation. NIH 3T3 cells were plated on a 10-cm-diameter dish at 106
cells per plate and transfected the next day with various expression constructs.
Cells were harvested 24 h posttransfection, and cell pellets were resuspended in
sucrose/Nonidet P-40 (NP-40) buffer containing 0.32 M sucrose, 3 mM CaCl2,
2 mM magnesium acetate, 0.1 mM EDTA, 10 mM Tris-HCl (pH 8.0), 1 mM
dithiothreitol, and 0.5% (vol/vol) NP-40 along with protease inhibitors (13). The
lysates were microcentrifuged at 500 3 g for 5 min at 4°C, and the supernatant
containing the cytoplasm was transferred to a fresh tube. The nuclei were washed
with 1 ml of sucrose buffer without NP-40, and then lysed in sodium dodecyl
sulfate (SDS) sample buffer by boiling. The protein concentration in each sample
was visually quantified on Coomassie-blue-stained SDS-polyacrylamide gel elec-
trophoresis (SDS-PAGE) gel, and equivalent amounts of protein were then
separated on an SDS–10% PAGE gel and visualized by Western blotting, as
described below. GFP-specific polyclonal antibody from Clontech was used at
recommended dilutions to visualize EGFP-CBFa2 and EGFP-CBFb in the pres-
ence and absence of CBFa2. Anti-cytosolic phospholipase A2 (cPLA2) specific
monoclonal antibody (Santa Cruz) and anti-retinoblastoma (Rb) specific mono-
clonal antibody (Pharmingen) were also used at recommended dilutions to probe
the blots for ascertaining the purity of the cytoplasmic fraction and nuclear
fraction, respectively.
Immunofluorescence. Coverslips with transfected cells were fixed in two dif-
ferent ways to avoid fixation artifacts. Cells were fixed either in cold (220°C)
methanol for 7 min or in 4% formaldehyde for 30 min. In the latter case, the fixed
cells were then permeabilized with 0.3% Triton buffer for 30 min. For experi-
ments involving transfection with GFP fusion constructs, cells were fixed only in
formaldehyde followed by permeabilization as described above, since methanol
has been shown to inhibit GFP fluorescent activation. Detection of fluorescent
signals was performed according to a modification of the procedure described by
Cullen (11). Fixed cells were blocked overnight with a solution containing PBS,
10% goat or horse serum (same as that of secondary antibody), 2% milk, and 3%
BSA. Transfected cells were incubated with primary antibodies diluted in Tween
buffer (PBS, 2% BSA, 0.5% Tween 20) for 2 h at room temperature. Cells were
then washed once with PBS for 5 min and twice with Triton buffer (PBS, 2%
BSA, 0.3% Triton X-100) for 10 min each. The fluorescence-labeled secondary
antibody was diluted in Triton buffer and added to transfected cells for 1 h at
room temperature. Cells were then washed once with PBS for 5 min, twice with
Triton buffer for 10 min each time, and once with PBS for 10 min before
mounting with 49,6-diamidino-2-phenylindole (DAPI)-antifade on a glass slide
for microscopy. Experiments were repeated three or more times.
Immunoprecipitation. pCBFB, pCBFB-MYH11, and related deletion con-
structs (pCBFB-MYH11DN2-11, pCBFB-MYH11DC390, pCBFB-MYH11DC303,
pCBFB-MYH11DC95) were translated in vitro with 35S-labeled methionine by
using the Promega reticulocyte lysate translation kit. pCbfa2 was translated in
vitro with or without radioactive methionine. Protein A-Sepharose-plus (Pierce)
was washed with PBS, then blocked with 2% BSA in PBS. Thirty microliters of
the blocked protein A was incubated with antibody a3043 for 2 h at 4°C on a
rotator and then washed twice with Triton buffer. The protein A beads were then
incubated overnight at 4°C with 35S-labeled CBFb, CBFb-SMMHC, and related
deletion proteins, in the presence or absence of cold in vitro-translated CBFa2.
The Sepharose beads were then collected by centrifugation and washed with
Triton buffer four times to remove any residual buffer. The beads were then
resuspended and boiled for 5 min in 25 ml of 23 SDS buffer. Ten microliters of
this buffer containing the eluted proteins was then analyzed by denaturing PAGE
and autoradiography.
Chemical cross-linking. Proteins were translated in vitro in the presence of
35S-labeled methionine by using the Promega reticulocyte lysate kit. They were
then diluted fivefold with PBS and incubated at room temperature for 1 h with
glutaraldehyde at a final concentration of 0.0025%. The reactions were stopped
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by addition of Tris (pH 8) and glycine at final concentrations of 25 and 192 mM,
respectively, and analyzed by denaturing PAGE and autoradiography.
Western blot analysis. Whole-cell extracts in SDS gel loading buffer were
prepared from NIH 3T3 cells (106 cells per dish) transfected with the appropriate
expression plasmids, separated by SDS–12% PAGE, and transferred to a nitro-
cellulose membrane. The membrane was blocked with Tris-buffered saline (TBS)
buffer (135 mM NaCl, 20 mM Tris [pH 7.5], 5% milk, and 0.1% Tween 20),
incubated for 2 h on a shaker at room temperature with an appropriate primary
antibody, washed with TBS buffer, and then incubated with a peroxidase-labeled
secondary antibody (KPL Inc.) at the recommended dilution in TBS for 1 h at
room temperature. Proteins were visualized by developing chemiluminescent
signal with reagents from Pierce and exposure to X-ray films.
Analysis of mouse embryonic fibroblasts. Generation of mice heterozygous for
the Cbfa2lz allele will be described elsewhere (33). Briefly, exons 7 and 8 of the
Cbfa2 gene were replaced with lacZ-bearing sequences in such a way that a
CBFa2-bgal fusion protein was synthesized from the modified Cbfa2 allele.
Female mice heterozygous for the Cbfa2lz allele (Cbfa2lz/1) were mated to a male
chimeric mouse generated from mouse embryonic stem cells heterozygous for a
knock-in inv(16) allele (CbfbCBFB-MYH11/1) (8). Embryos from this cross were
isolated at 11.5 days postcoitus (dpc), the yolk sacs and anterior portions (heads)
of the embryos were removed, and the rest of each embryo was used to generate
mouse embryonic fibroblasts. Embryos were suspended in 5 ml of HEPES-
buffered saline and passed through an 18-gauge needle, and the cells were
collected by centrifugation, resuspended in 5 ml of Dulbecco’s modified Eagle
medium–10% fetal calf serum, and then passed through a 21-gauge needle.
Disaggregated cells from individual embryos were plated in one well (35-mm-
diameter) of a six-well tissue culture plate and cultured at 37°C. The mouse
embryonic fibroblasts were passed one additional time in duplicate plates, and
the cells from one plate were processed for b-galactosidase activity following
standard protocols. Fibroblasts with both Cbfa2lz/1 and CbfbCBFB-MYH11/1 alleles
were further stained with DAPI for nuclear visualization by standard procedures.
Inheritance of CbfbCBFB-MYH11 allele was demonstrated by the presence of the
CBFb-SMMHC fusion protein, assayed by Western blot analysis of the mouse
embryonic fibroblasts, as described previously (8).
All figures were made with Adobe Photoshop version 4.0 for Macintosh.
RESULTS
Coimmunoprecipitation of CBFb and of CBFb-SMMHC
and its deletions with CBFa2. The ability of the CBFb-SMMHC
deletion proteins to interact with CBFa2 was characterized by
immunoprecipitation of in vitro-translated proteins. Fig. 1A
shows the in vitro-translated 35S-labeled proteins used in the
reactions. To assess binding to CBFa2, a polyclonal antibody
that recognizes the CBFa2 runt domain (a3043) was first
bound to protein A-Sepharose beads. The matrix-bound an-
tibody was then incubated with or without nonradioactive
CBFa2 (in vitro-translated from pCbfa2) in conjunction
with radioactively labeled CBFb, CBFb-SMMHC, CBFb-
SMMHCDC390, CBFb-SMMHCDC303, CBFb-SMMHCDC95, and
CBFb-SMMHCDN2-11 (in vitro-translated from pCBFB, pCBFB-
MYH11, pCBFB-MYH11DC390, pCBFB-MYH11DC303, pCBFB-
MYH11DC95, and pCBFB-MYH11DN2-11, respectively). As seen
in Fig. 1B, lanes 2 and 4, CBFb and full-length CBFb-SMMHC
were immunoprecipitated with CBFa2, as expected. The protein
with the N-terminal deletion CBFb-SMMHCDN2-11 failed to be
immunoprecipitated with CBFa2 (Fig. 1B, lane 12). Those with
the C-terminal deletions of CBFb-SMMHC, which retain the N-
terminal end, interacted with CBFa2 and were immunoprecipi-
tated (Fig. 1B, lanes 6, 8, and 10). The 35S-labeled CBFa2 was im-
munoprecipitated in the presence of the antibody (lane 14) but
not in its absence (lane 13), indicating the specificity of the inter-
action.
Protein expression from plasmid constructs after transient
transfection. The expression of CBFa2, CBFb, CBFb-SMMHC,
and the various deletion proteins after transient transfection of
NIH 3T3 cells was tested by Western blotting. The polyclonal
antibody against CBFa2, a3043, was used to probe whole-cell
extracts from untransfected NIH 3T3 cells and from NIH 3T3
cells transfected with pCbfa2, pEGFP-C2 (empty vector), and
pEGFP-Cbfa2 (Fig. 1C, lanes 1 to 4). Proteins of expected
sizes (49 kDa for CBFa2 and 76 kDa for EGFP-CBFa2) were
detected in cells transfected with pCbfa2 and pEGFP-Cbfa2
(Fig. 1C, lanes 2 and 4, respectively). The ;50 kDa band pres-
ent in all the samples (Fig. 1C, lanes 1 to 4) most likely results
from nonspecific binding of the antibody to an endogenous pro-
tein. Cell extracts from NIH 3T3 cells transfected with pCBFB-
MYH11 and the deletion constructs with or without EGFP
fusion were probed with b141.2, a monoclonal antibody against
CBFb (Fig. 1C, lanes 5 to 17 for plasmids pCBFB-MYH11,
pCBFB-MYH11DN2-11, pCBFB-MYH11DC390, pCBFB-
MYH11DC303, pCBFB-MYH11DC95, pCBFB, pEGFP-CBFB-
MYH11, pEGFP-CBFB-MYH11DN2-11, pEGFP-CBFB-
MYH11DC390, pEGFP-CBFB-MYH11DC303, pEGFP-CBFB-
MYH11DC95, pEGFP-CBFB, and pEGFP-C2, respectively).
FIG. 1. Characterization of CBFa2, CBFb, CBFb-SMMHC, and the deletion mutants. (A) Generation of protein products by in vitro translation. [35S]methionine-
labeled proteins were produced by in vitro translation, separated by gel electrophoresis, and detected by autoradiography. The intense bands at the bottom of the gel
are the free [35S]methionine. (B) Interactions between CBFa2 and the deletion mutants. The protein products shown in panel A were immunoprecipitated with
polyclonal antibody a3043, in the presence or absence of cold in vitro-translated CBFa2. (C) Expression of cDNA constructs after transient transfection into NIH 3T3
cells. The Western blot with extracts derived from transiently transfected NIH 3T3 cells was probed with a3043 to detect CBFa2 and EGFP-CBFa2 (lanes 1 to 4). The
relevant proteins are shown by arrowheads in lanes 2 and 4. Similarly, the antibody b141.2 was used to identify CBFb, CBFb-SMMHC, the deletion proteins, and their
GFP fusions by Western blotting of cellular extracts (lanes 5 to 17). Protein molecular mass markers are shown on the right sides of panels B and C.
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Again, proteins of expected sizes were visible in all the trans-
fected cell samples. Protein bands corresponding to the endog-
enous CBFb were detected in certain samples (Fig. 1C, lanes
7 to 9), although the variability suggests that these could be de-
rived from degradation of the higher-molecular-weight proteins.
Subcellular localization of CBFa2, CBFb, and CBFb-
SMMHC after transient transfection. Plasmids containing
full-length coding sequences (pCbfa2, pCBFB, and pCBFB-
MYH11) were transiently transfected into NIH 3T3 cells to
examine the subcellular localization of CBFa2, CBFb, and
CBFb-SMMHC. Expression and localization of these proteins
were detected by primary antibodies a3043 and b141.2, fol-
lowed by immunofluorescence labeling with fluorescein and
Texas-red-conjugated secondary antibodies. The levels of en-
dogenous CBFb and CBFa2 proteins, though detectable by gel
shifts (unpublished data), were below the limits of detection by
immunofluorescence. Transient transfection of GFP fusion con-
structs (pEGFP-Cbfa2, pEGFP-CBFB, and pEGFP-CBFB-
MYH11) was used as an independent method of assessing
subcellular locations, and the results were in agreement with
those of immunofluorescence staining.
Transiently expressed CBFa2 (from plasmid pCbfa2) was
localized completely in the nuclei of transfected NIH 3T3 cells
(Fig. 2A1). The fluorescent staining was distributed throughout
the nucleus but excluded from nucleoli-like structures (com-
pare Fig. 2A1 and A2). This nuclear localization of CBFa2 was
confirmed by pEGFP-Cbfa2 transfection (Fig. 2B1) and was
similar to published results for CBFa1 (28). Transiently ex-
pressed wild-type CBFb (from plasmid CBFB) was found even-
ly distributed in both the cytoplasm and nuclei of transfected
cells (Fig. 2C1). This localization pattern was confirmed with
EGFP-CBFb (Fig. 2D1) and was similar to the pattern of
EGFP alone (1).
CBFb-SMMHC (from plasmid pCBFB-MYH11), on the oth-
er hand, was localized along stress-fiber-like filaments and ag-
gregates (Fig. 2E1). Observations from pEGFP-CBFB-MYH11
transfection were consistent with the immunofluorescence re-
sults (Fig. 2F1). Some of the CBFb-SMMHC protein was lo-
calized in the nuclei in a diffuse pattern in certain transfected
cells (Fig. 2F1 and Fig. 4C1), though the majority of the pro-
tein showed localization along the filaments and aggregates.
The subcellular localization of CBFb-SMMHC could be clas-
FIG. 2. Subcellular localization of CBFa2, CBFb, and CBFb-SMMHC in transiently transfected cells. NIH 3T3 cells were transfected with pCbfa2 (A1 and A2),
pEGFP-Cbfa2 (B1 and B2), pCBFB (C1 and C2), pEGFP-CBFB (D1 and D2), pCBFB-MYH11 (E1 and E2), and pEGFP-CBFB-MYH11 (F1 and F2). Odd-numbered
panels show fluorescent signals, while even-numbered panels show DAPI staining of the same fields. Panel A1 shows signal detected with a3043 and a Texas-red-labeled
secondary antibody, panels C1 and E1 show signals detected with b141.2 and a fluorescein-labeled secondary antibody, and panels B1, D1, and F1 show the auto-
fluorescent signal of GFP fused to the respective proteins. The antibodies failed to detect the endogenous proteins (compare the untransfected cell in panel A1 with
panel A2, as well as that in panel C1 with panel C2).
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sified into three categories based on the level of expression:
cells which had a low level of expression showed localization
along the filaments (Fig. 2E1 and Fig. 4A1); a moderate level
of expression resulted in accumulation of the protein along the
filaments, leading to a speckled pattern (Fig. 4B1); and a high-
er expression level of CBFb-SMMHC showed aggregation,
and the protein seemed to accumulate in higher-order struc-
tures (Fig. 4C1).
Full-length CBFa2 can bring CBFb into the nucleus.
pCBFB and pCbfa2 were cotransfected into NIH 3T3 cells and
immunofluorescence labeling was carried out as described
above. Two of the four cells shown in Fig. 3A expressed the
transiently transfected pCbfa2, as shown by the green signal in
Fig. 3A1, while one of these two cells also expressed the tran-
siently transfected pCBFB as shown by the red signal in Fig.
3A2. As shown in Fig. 3A1, CBFa2 was localized completely in
the nucleus, similar to the pattern observed when it was ex-
pressed alone. Intriguingly, CBFb also was localized to the
nucleus, and it was distributed in a pattern similar to that of
CBFa2 (Fig. 3A2). This suggests that full-length CBFa2 is able
to bring CBFb into the nucleus. This nuclear localization of
CBFb by CBFa2 was dose dependent. When equal molar
amounts of both plasmid DNAs were used for transfection, as
in the cells shown in Fig. 3, approximately 88% of the cells
expressing both CBFb and CBFa2 showed nuclear localization
of CBFb. Increasing the amount of pCbfa2 DNA relative to
that of pCBFB increased the proportion of cells in which
CBFb localized to the nucleus. When the amount of pCbfa2
DNA was fivefold molar excess relative to that of pCBFB
DNA, in approximately 93% of the cotransfected cells CBFb
and CBFa2 colocalized in the nucleus. Increasing the pCbfa2
DNA amount to ninefold molar excess relative to that of pCBFB
DNA resulted in almost 100% of the doubly transfected cells
having CBFb in nuclei along with CBFa2. Cotransfections with
pEGFP-CBFB and pCbfa2 gave comparable results (Fig. 3B1,
B2, and B3).
The nuclear transport of CBFb by CBFa2 was also con-
firmed by cell fractionation studies. Cytoplasmic and nu-
clear fractions prepared from NIH 3T3 cells transfected with
pEGFP-CBFB and/or pEGFP-Cbfa2 were probed with a GFP-
specific antibody on Western blots. As shown in Fig. 3C, trans-
fected EGFP-CBFa2 was predominantly localized in the nu-
clear fraction (lanes 7 and 8), whereas the transfected EGFP-
CBFb was mainly present in the cytoplasmic fraction (lanes 3
and 4). On the other hand, EGFP-CBFb was found mostly in
FIG. 3. CBFa2 brings CBFb into the nucleus when coexpressed. Cells were cotransfected with pCbfa2 and pCBFB (A1, A2, and A3) or with pCbfa2 and pEGFP-
CBFB (B1, B2, and B3). Panels A1, A2, and A3 represent images of the same field seen through different filters, as do panels B1, B2, and B3. CBFa2 was detected
with antibody a3043 and a fluorescein-labeled (A1) or a Texas-red-labeled (B1) secondary antibody. CBFb localization was detected with b141.2 and a Texas-red-
labeled secondary antibody (A2). Panel B2 shows the autofluorescence of EGFP-CBFb. Cells in panels A3 and B3 were stained by DAPI. (C) Cytoplasmic and nuclear
fractionation of the transfected cells is shown. NIH 3T3 cells transfected with pEGFP (lanes 1 and 2), pEGFP-CBFB (lanes 3 and 4), pEGFP-CBFB plus pCbfa2 (lanes
5 and 6), and pEGFP-Cbfa2 alone (lanes 7 and 8) were fractionated into cytoplasmic and nuclear fractions, which were separated on SDS-PAGE gel and probed by
Western blotting with a GFP-specific antibody. The quality of cell fractionation was analyzed by probing with antibodies for cPLA2 (cytoplasmic) and Rb (nuclear).
C, cytoplasmic fraction; N, nuclear fraction. Molecular mass markers are shown to the right in panel C.
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the nuclear fraction after cotransfection with pCbfa2 (lanes 5
and 6), consistent with the immunofluorescence data.
CBFb-SMMHC sequesters CBFa2 along filaments and ag-
gregates. When CBFa2 and CBFb-SMMHC were coexpressed
in NIH 3T3 cells through transient cotransfection (plasmids
pCbfa2 and pCBFB-MYH11) and analyzed by immunofluo-
rescence labeling, CBFb-SMMHC assembled into the same fil-
amentous or aggregated structures as it did when expressed
alone (Fig. 4A1). However, CBFa2 colocalized with CBFb-
SMMHC along the filaments and aggregates (Fig. 4A2). Sim-
ilar results were obtained when pEGFP-Cbfa2 was cotrans-
fected with pCBFB-MYH11 (Fig. 4B1, B2, and B3) and when
pCbfa2 was cotransfected with pEGFP-CBFB-MYH11 (Fig.
4C1, C2, and C3). Occasionally, CBFa2 and CBFb-SMMHC
proteins were found in both the nucleus and cytoplasm (Fig.
4C1 and C2). In more than 95% of the cells that expressed both
transfected genes, CBFa2 colocalized with CBFb-SMMHC
along the filaments and aggregates. In cells where the concen-
tration of CBFb-SMMHC was much lower than that of CBFa2
(based on immunofluorescence intensity), while some CBFa2
colocalized with CBFb-SMMHC outside the nucleus, the re-
maining excess of CBFa2 protein localized to the nucleus.
We attempted to confirm the CBFa2 sequestration by CBFb-
SMMHC using cell fractionation analysis, but we found that
the CBFb-SMMHC protein was always present in the nuclear
fraction, regardless of whether it was expressed alone or in
combination with CBFa2 (1). This result could be explained by
the fact that the MHC molecule multimerizes and forms large
aggregates at salt concentrations below 200 mM. The low-salt-
concentration treatment of cells for the disruption of cytoplas-
mic membranes (less than 15 mM) (13) would therefore result
in the formation of CBFb-SMMHC aggregates, which would
then precipitate with the nuclear fraction in the subsequent
centrifugation step. This intrinsic myosin coprecipitation with
the nuclear fraction was confirmed, as endogenous nonmuscle
MHC (NMMHC) was present mainly in the nuclear fraction in
such preparations (1) although NMMHC have been shown to
be cytoplasmic proteins associated with actin (19). We also at-
FIG. 4. CBFb-SMMHC sequesters CBFa2 along filaments and aggregates. (A1, A2, and A3) NIH 3T3 cells were cotransfected with pCbfa2 and pCBFB-MYH11.
CBFb-SMMHC localization was detected with antibody b141.2 and a fluorescein-labeled secondary antibody (panel A1), and CBFa2 localization was detected with
antibody a3043 and a Texas-red-labeled secondary antibody (panel A2). (B1, B2, and B3) Localization of EGFP-CBFa2 and CBFb-SMMHC when cotransfected.
CBFb-SMMHC localization is shown by the red signal (b141.2 and a Texas-red-labeled secondary antibody) in panel B1, while EGFP-CBFa2 localization is shown by
the green autofluorescent signal in panel B2. (C1, C2, and C3) Cotransfected EGFP-CBFb-SMMHC (panel C1) and CBFa2 (panel C2), which were detected in a
fashion similar to that described for panel B. (A3, B3, and C3) DAPI staining of the respective fields.
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tempted to solubilize myosin by raising the salt concentration
during cell lysis, but we were able only to partially solubilize
CBFb-SMMHC, while at the same time nuclear proteins start-
ed to leak into the cytoplasmic fraction (1). Therefore, we
could not determine with accuracy the percentages of CBFb-
SMMHC and CBFa2 in the cytoplasmic and nuclear compart-
ments using cell fractionation.
Sequestration of CBFa2 results from direct interaction be-
tween CBFa2 and CBFb-SMMHC. The first 11 amino acids
of the CBFb protein are required for the binding to CBFa2
(44). A CBFb-SMMHC protein missing this region (CBFb-
SMMHCDN2-11) failed to interact with CBFa2, as seen by its
inability to be coimmunoprecipitated (Fig. 1B). When pCBFB-
MYH11DN2-11 was transfected into NIH 3T3 cells, the ex-
pressed protein localized along the filaments in the cytoplasm,
similarly to the full-length protein (Fig. 5A1). However, when
coexpressed with CBFa2, the deletion protein did not change
the nuclear location of CBFa2. As shown in Fig. 5B, CBFb-
SMMHCDN2-11 and CBFa2 behaved independently of each
other: CBFb-SMMHCDN2-11 was distributed mainly in the
cytoplasm along filament-like structures, whereas CBFa2 re-
mained exclusively in the nucleus. This observation was con-
firmed by using EGFP-CBFb-SMMHCDN2-11 (1).
C-terminal SMMHC domain of CBFb-SMMHC is required
for CBFa2 sequestration. We next determined whether CBFa2
sequestration was dependent on the myosin part of the chi-
meric protein CBFb-SMMHC. Constructs with deletions at
the C-terminal end of CBFb-SMMHC (Fig. 1) were used for in
vitro cross-linking analysis to test the ability of their protein
products to dimerize and multimerize. In vitro-translated pro-
teins were incubated under conditions allowing dimerization in
the presence or absence of glutaraldehyde, which covalently
cross-links the dimerized proteins. Full-length CBFb-SMMHC
was capable of forming dimers and tetramers as seen by the
presence of more-slowly migrating complexes (Fig. 6, lane 6).
CBFb-SMMHCDC95 was able to dimerize (Fig. 6, lane 8), al-
though with somewhat less efficiency than CBFb-SMMHC.
Removing 175 amino acids from the C-terminal end fur-
ther decreased the efficiency of dimerization (1). Any fur-
ther deletion in the C-terminal end abrogated the ability of
CBFb-SMMHC to assemble into dimers, as seen for CBFb-
SMMHCDC303 (lane 10) and CBFb-SMMHCDC390 (lane 12).
CBFa2 (lane 2) and CBFb (lane 4) did not dimerize under
these conditions, as expected from previous studies (17, 50).
The subcellular localization of CBFb-SMMHCDC95, CBFb-
SMMHCDC303, and CBFb-SMMHCDC390, in the presence or ab-
sence of CBFa2, was then determined by immunofluorescence.
CBFb-SMMHCDC95 (from plasmid pCBFB-MYH11DC95), the
deletion protein which retains the ability to dimerize, was lo-
calized to the cytoplasm in the majority of the cells when trans-
fected alone (Fig. 5C1). Interestingly, CBFb-SMMHCDC95
seemed to localize almost entirely to the cytoplasm, with al-
most no protein evident in nuclei and with no prominent fila-
ment-like structures in the cytoplasm. Despite this subtle but
consistent difference in subcellular localization compared to
full-length CBFb-SMMHC, CBFb-SMMHCDC95 retained the
FIG. 5. Immunofluorescence of CBFb-SMMHC deletion proteins and coexpressed CBFa2. CBFb-SMMHC deletion proteins and CBFa2 were detected with b141.2
and a3043, respectively, plus appropriate secondary antibodies. (A and B) Immunofluorescence labeling of NIH 3T3 cells transfected with pCBFB-MYH11DN2-11, either
alone (panels A1 and A2) or with pCbfa2 (panels B1, B2, and B3). Panels A1 and A2 show the same field with the CBFb-SMMHCDN2-11 localization in green and
DAPI-stained nuclei in blue, respectively. Localization of CBFb-SMMHCDN2-11 is again shown in green in panel B1, while cotransfected CBFa2 is shown in red in panel
B2. (C1 and C2) Immunofluorescence labeling of cells transfected with only pCBFB-MYH11DC95. (D) Cells cotransfected with pCBFB-MYH11DC95 (panel D1) and
pCbfa2 (panel D2). CBFb-SMMHCDC303 was labeled in green when transfected alone (E1) or cotransfected (F1) with CBFa2, which was labeled in red (F2). The panels
labeled with the same letter are views of the same fields. (A2, B3, C2, D3, E2, and F3) DAPI staining showing the nuclei of cells in the respective fields.
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ability to sequester CBFa2 when coexpressed (Fig. 5D1, D2, and
D3). On the other hand, deletion proteins CBFb-SMMHCDC303
(Fig. 5E1 and E2) and CBFb-SMMHCDC390 (1), which failed
to form dimers, showed diffuse distribution all over the cells
when transfected alone (Fig. 5E1) and were transported into
the nucleus when cotransfected with CBFa2 (Fig. 5F1 to F3).
These results were also confirmed with EGFP fusion proteins
(1). These data suggest that the coiled-coil domain is essential
for the subcellular localization of CBFb-SMMHC and for its
ability to sequester CBFa2.
CBFb-SMMHC colocalizes with actin. The pattern of local-
ization of the inv(16) fusion protein is similar to that of actin
stress fibers. To determine if CBFb-SMMHC colocalizes with
actin, NIH 3T3 cells were transfected with pCBFB-MYH11 or
pEGFP-CBFB-MYH11 and subjected to immunofluorescence
labeling with b141.2 (for CBFb-SMMHC) and Texas-red-la-
beled phalloidin, which specifically interacts with actin. The
data in Fig. 7 clearly illustrate that CBFb-SMMHC and EGFP-
CBFb-SMMHC colocalized with actin filaments (compare Fig.
7A1 with A2 and Fig. 7B1 with B2). Again, some of the EGFP-
CBFb-SMMHC protein can be seen in the nucleus in addition
to the filamentous localization in the cytoplasm (Fig. 7B1).
NIH 3T3 cells were also transfected with pCBFB or pEGFP-
CBFB. In contrast to CBFb-SMMHC, CBFb and EGFP-
CBFb were distributed throughout the cell (Fig. 7C1 and D1),
the localization showing no correlation with actin localization
(Fig. 7C2 and D2).
Colocalization of CBFa2 and CBFb-SMMHC in vivo.
Through homologous recombination in mouse ES cells, the
bacterial lacZ gene was fused in frame to the mouse Cbfa2
gene, downstream from the runt domain (33). The expression
of the Cbfa2lz allele is under the control of endogenous Cbfa2
promoter, resulting in near-physiological levels of Cbfa2-bgal
fusion protein in the cells of Cbfa2lz/1 mice. The chimeric
Cbfa2-bgal protein produced retained its ability to interact
with CBFb through the runt domain, while the bgal portion of
FIG. 6. Glutaraldehyde cross-linking of CBFb, CBFb-SMMHC, and the de-
letion proteins. Proteins as labeled at the top of the lanes were translated in vitro
in the presence of [35S]methionine. Cross-linking of each protein was accom-
plished by incubation in the presence (even-numbered lanes) or absence (odd-
numbered lanes) of glutaraldehyde. Slow mobility bands were observed for
CBFb-SMMHC and CBFb-SMMHCDC95 but not for CBFa2, CBFb, CBFb-
SMMHCDC303, and CBFb-SMMHCDC390. Protein molecular mass markers are
shown on the right.
FIG. 7. CBFb-SMMHC colocalizes with actin filaments, while CBFb does not. NIH 3T3 cells were transfected with pCBFB-MYH11 (A1 and A2), pEGFP-CBFB-
MYH11 (B1 and B2), pCBFB (C1 and C2), and pEGFP-CBFB (D1 and D2). Proteins were detected with b141.2 plus a fluorescein isothiocyanate-labeled secondary
antibody (panels A1 and C1) and Texas-red-conjugated phalloidin (panels A2, B2, C2, and D2). Panels B1 and D1 show the autofluorescent signal from the GFP fusion
proteins.
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the protein permitted detection of the protein by the relative-
ly sensitive 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside
assay. Matings were set up between Cbfa2lz/1 mice and chi-
meric mice made with CbfbCBFB-MYH11/1 ES cells, which pro-
duce a CBFb-SMMHC fusion protein (8). Mouse embryonic
fibroblasts isolated from 11.5-dpc embryos derived from such
matings contained either only the Cbfa2lz allele or both the
Cbfa2lz and CbfbCBFB-MYH11/1 alleles. b-Galactosidase activity
was detected mainly in the nuclei of mouse embryonic fibro-
blasts derived from Cbfa2lz/1 embryos (Fig. 8A) (92% of the
cells had expression exclusively in the nucleus, and 8% had
expression in both the cytoplasm and nucleus), whereas a sig-
nificant amount of b-galactosidase activity was found in the
cytoplasm of fibroblasts containing the CbfbCBFB-MYH11/1 al-
lele (Fig. 8B). Seventy percent of the cells had expression only
in the cytoplasm (e.g., the cells shown on the right in Fig. 8B),
29% had it in both the cytoplasm and the nucleus (e.g., the cell
shown on the left in Fig. 8B), and 1% had it only in the nucleus.
The result demonstrates that cytoplasmic sequestration of
CBFa2 by the CBFb-SMMHC fusion protein also occurs at
normal physiological levels of the proteins.
DISCUSSION
Genes encoding subunits of the core binding factor CBF are
frequently disrupted by chromosome rearrangements in hu-
man leukemias. Translocation t(8;21), found in AML subtype
M2, generates a fusion protein, AML1-ETO. This protein has
been shown to inhibit both AML1/CBFa2- and C/EBPa-de-
pendent transcriptional activation, although the mechanism
for this inhibition remains unknown (14, 30, 52). AML1-ETO
can also dominantly suppress CBF function, as shown in a
mouse knock-in model (38, 55). The AML1-Evi-1 chimeric
protein, produced in t(3;21) associated with t-MDS, t-AML,
and CML-BC, can suppress transactivation by intact AML1/
CBFa2 (56). Again, the mechanism for such suppression is not
fully understood. In this study we have addressed the mecha-
nism by which the inv(16) chimeric protein CBFb-SMMHC
plays a dominant negative role. Our results suggest that CBFb-
SMMHC plays a dominant negative role by sequestering
CBFa2/AML1 to cytoskeletal structures, thus initiating a pro-
cess towards leukemia by disrupting transcriptional regulation
of genes controlled by CBFa2/AML1.
Upon transient transfection into NIH 3T3 cells, CBFa2
was localized in the nucleus whereas CBFb was distributed
throughout the cell. CBFb-SMMHC was located predomi-
nantly in the cytoplasm, forming filamentous or aggregated
structures. We did observe some CBFb-SMMHC protein in
the nuclei of the transfected cells, in addition to the filaments
and aggregates in the cytoplasm, but we did not observe the
nuclear rod-like structure that we previously found in clonal
NIH 3T3 cell lines overexpressing CBFb-SMMHC (53). This is
probably due to the difference in expression level and/or the
difference between transient and stable transfections. In fact,
the rod-like structures were found only in cell lines expressing
high levels of the CBFb-SMMHC protein and only in a small
percentage (10 to 40%) of cells within a cell population (1, 53).
On the other hand, the stress fibers formed by CBFb-SMMHC
were evident in most of the cells stably expressing CBFb-
SMMHC, regardless of expression level (1, 53).
In the present study, we demonstrated that CBFb localized
to the nucleus when cotransfected with full-length CBFa2. The
likely mechanism for this nuclear localization of CBFb is that
CBFa2 heterodimerizes with CBFb in the cytoplasm and me-
diates the transport of the heterodimer into the nucleus. Nu-
clear localization of CBFa2 can be overridden by CBFb-
SMMHC, which forms homodimers and multimers and inter-
acts with cytoskeletal molecules. The sequestration of CBFa2
by CBFb-SMMHC is dependent on the heterodimerization
domain in CBFb that mediates interaction with the CBFa
subunits. The truncated protein with a deletion of the CBFa2-
interacting domain, CBFb-SMMHCDN2-11, lost the ability to
sequester CBFa2, even though it retained the ability to assem-
ble into cytoskeletal structures (Fig. 5B1 to B3). Sequestration
of CBFa2 by CBFb-SMMHC is also dependent on the pres-
ence of the C-terminal SMMHC domain. Deletions of the C-
terminal SMMHC domain disrupted the ability of the chimeric
protein to dimerize and to interact with other cytoskeletal
proteins, most likely other myosin family members such as
NMMHC, and compromised its ability to sequester CBFa2. In
fact, once the C-terminal SMMHC domain was lost, the trun-
cated CBFb-SMMHC proteins behaved like wild-type CBFb
in that they were no longer localized along the cytoskeletal
structures and localized to the nucleus when coexpressed with
CBFa2 (Fig. 5E and F).
Our efforts to confirm these results in the samples from
patients with inv(16) yielded equivocal results, most likely be-
cause the endogenous levels of the proteins were too low to be
identified by immunofluorescence (1). However, CBFa2 se-
FIG. 8. In vivo sequestration of Cbfa2 by Cbfb-SMMHC. Embryonic fibroblasts were isolated from 11.5-dpc mouse embryos, cultured briefly in vitro, and stained
for the Cbfa2-bgal protein. (A) A fibroblast from an embryo of Cbfa2lz/1 genotype stained for bgal. (B1) Fibroblasts from an embryo of Cbfa2lz, CbfbCBFB-MYH11/1
genotype stained for bgal. Arrows indicate the bgal staining. (B2) DAPI staining of the same field as shown in panel B1.
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questration was observed in vivo, in a mouse gene-targeting
model. This result not only confirmed the findings obtained
with transient transfections in cultured cells which could po-
tentially result from overexpression, but also demonstrated the
dominant nature of this sequestration, since both wild-type
CBFb and CBFb-SMMHC proteins are expressed in the Cbfb-
MYH11 knock-in mice (8).
The mechanism for the dominant nature of the CBFa2 se-
questration in vivo is still not clear. At least two possibilities
exist: one is that CBFb-SMMHC is more stable than the wild-
type CBFb and therefore has higher concentration in the cells,
and the other is that CBFb-SMMHC binds CBFa2 better than
does CBFb. Results from our previous study (8) showed that
CBFb-SMMHC was expressed at a level similar to that of the
wild-type CBFb in the Cbfb-MYH11 knock-in embryos. CBFb-
SMMHC and CBFb were found to be expressed at comparable
levels in leukemia cells from a number of patients as well (9,
10). However, Western blotting is not very quantitative, and
variations up to fivefold have been observed. Therefore, it is
possible that the fusion protein is more stable than the wild-
type CBFb. On the other hand, the binding property of CBFb-
SMMHC to CBFa2 has not been studied in detail, since pu-
rified full-length CBFb-SMMHC in large enough quantity for
such experiments is not available. Future investigations are
needed to find out if either or both of these two factors con-
tribute to the dominant sequestration of CBFa2 by CBFb-
SMMHC.
We observed that transfected CBFb was localized through-
out cells, with some cytoplasmic predominance. In addition,
the transfected CBFb did not colocalize with actin stress fibers
(Fig. 7C and D). This differs from a recent study which showed
that CBFb colocalizes with actin by immunofluorescent stain-
ing and fractionation (47). The reason for this difference is not
clear, but it could be attributed to the differences in the CBFb
isoforms used (CBFb187 versus CBFb182), in the cell types
used (REF52 cells versus NIH 3T3 cells), and the detergent
treatments employed.
A previous study showed that truncated CBFa1/PEBP2aA
can bring CBFb into the nucleus whereas full-length CBFa1/
PEBP2aA cannot (28). This leaves open the question as to
how CBFb localizes to the nucleus to enable formation of a
nuclear heterodimer with full-length PEBP2aA. One possible
explanation for the differences between our data and those
reported by Lu et al. (28) is that different CBFa proteins and
CBFb isoforms were used by the two groups. While we used
CBFa2, or AML1, the protein product of the gene involved in
human leukemias, Lu et al. used PEBP2aA, or CBFa1, which
differs from CBFa2 in sequence and has been shown to be
important for osteogenesis (12, 20, 32, 40). These two CBFa
proteins may have different affinities for CBFb. In the case of
CBFb, we used the CBFb187 isoform, while the CBFb182 iso-
form was used by Lu et al. (28). These two isoforms have two
different C-terminal ends that are the result of alternative
splicing, which may be responsible for the differences between
the observations made by the two groups. Finally, the concen-
trations of CBFa1, CBFa2, and CBFb achieved in the two
studies may have differed, which would have influenced the
extent of CBFa:CBFb heterodimerization.
CBFb-SMMHC-mediated CBFa2 sequestration can at least
partially explain the dominant negative suppression of CBF
function by CBFb-SMMHC in hematopoiesis and leukemo-
genesis. Due to the limited sensitivities of the assays and the
nature of transient transfection, we cannot rule out the possi-
bility that free CBFa2 was present in the nuclei of some cells.
Therefore, additional mechanisms, such as reduced binding
of target DNA sequences by CBFb-SMMHC:CBFa hetero-
dimers, may also contribute to the dominant negative effect on
CBF function of CBFb-SMMHC. However, it has been pos-
tulated that CBFa2 is quantitatively limiting in vivo, since
hematopoietic progenitor cells are either reduced in number
or have decreased capacity to differentiate in Cbfa21/2 mice
(48). Therefore, substantial reduction of functional CBFa2
protein in the nucleus resulting from CBFb-SMMHC seques-
tration is probably sufficient to cause defective CBF function,
leading to dysregulation of downstream genes and contributing
to leukemogenesis.
The functional significance of CBFa2 sequestration by
CBFb-SMMHC is evident in the following two sets of studies.
First, it was recently demonstrated that CBFb-SMMHC can
reduce CBF DNA-binding and inhibit the G1-to-S cell cycle
transition in cultured myeloid and lymphoid cells (6, 7). These
effects were demonstrated to require the ability of CBFb-
SMMHC to interact with CBFa2 and the presence of the C-
terminal SMMHC domain, using deletion constructs similar to
those described here (7). These effects on CBF DNA-binding
and cell cycle could therefore be explained by CBFa2 seques-
tration. Secondly, CBFa2 sequestration by CBFb-SMMHC in
mouse embryonic cells as described in this study correlates
with the ability of CBFb-SMMHC to block CBF function and
disrupt hematopoiesis in mouse embryos. Future efforts will be
aimed at confirming whether the sequestration of CBFa2 in
vivo does in fact result in pathogenesis. This could potentially
be demonstrated by generating knock-in mice expressing chi-
meric proteins with abrogated ability to dimerize or by substi-
tuting for the myosin chain an unrelated cytoskeletal protein.
Targeted strategies to overcome or eliminate CBFa2 seques-
tration will be tested in cell culture and whole-animal models
to see if CBFb-SMMHC pathologic function can be subverted;
the results will have clinical implications for leukemia manage-
ment in the future.
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